FDA Clears New Blood Test for Alzheimer’s Disease Diagnosis
A new blood test, Lumipulse, has been cleared by the U.S. Food and Drug Administration (FDA) to assist in diagnosing Alzheimer's disease. This test detects amyloid plaque, a key marker for the disease, offering a less invasive diagnostic method compared…
Champaign Urbana & Springfield Decatur, IL, November 9, 2026 — The U.S. Food and Drug Administration (FDA) has cleared a new blood test designed to aid in the diagnosis of Alzheimer’s disease. The test, named Lumipulse, detects amyloid plaque, which is recognized as a key biological marker associated with the disease.
This clearance marks a step forward in diagnostic capabilities for Alzheimer’s. Amyloid plaque accumulation in the brain is a significant hallmark of Alzheimer’s disease. Previously, definitive detection often relied on more invasive procedures such as positron emission tomography (PET) scans or lumbar punctures to collect cerebrospinal fluid.
The Lumipulse test offers a less invasive alternative for identifying the presence of amyloid plaques. According to the FDA’s indication, the test is intended for individuals aged 55 and older who are experiencing symptoms of cognitive decline. It is crucial to note that the Lumipulse test is meant to be used as an aid in diagnosis and should be employed in conjunction with other clinical evaluations. It is not intended to be used as a standalone diagnostic tool for Alzheimer’s disease.
Experts suggest that early detection of conditions like Alzheimer’s can have a significant impact on patient care. Facilitating an earlier diagnosis can lead to improvements in quality of life for individuals and their families. It also enables more timely and effective care planning and the exploration of available treatment options.
Information regarding the specific timeline of the clearance process or details about the manufacturer of the Lumipulse test were not provided in the summary. The summary also did not specify the exact nature of the other medical evaluations that should accompany the blood test.
Story summarized from the original created by LeAnne Gendreau on www.wandtv.com, see more information here.
Media gallery
